Anavex Life Sciences is making strides in the field of neurodegenerative disease research with its promising investigational therapy, Anavex 2-73. This small molecule, known scientifically as blarcamesine, is being developed to help manage symptoms of conditions such as Parkinson’s disease, Alzheimer’s, and Rett syndrome. Anavex 2-73 functions by activating SIGMAR1, a receptor protein involved in maintaining cell health and survival,...
Anavex Life Sciences has recently announced significant progress in its pursuit of
developing effective treatments for neurodegenerative disorders. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), has demonstrated
promising results in a 48-week Phase 2 extension study involving patients with
Parkinson’s disease dementia.
The study, which is an open-label extension of a prior double-blind, placebo-controlled trial,
examined...
Edgard Corona, the visionary founder and CEO of Smart Fit,
has spent over 30 years shaping the fitness landscape. With an unwavering
commitment to providing affordable fitness options, Corona has tr ansformed
Smart Fit into a leading fitness brand in Latin America, with over 1,200 gyms
in 15 countries.
Corona's journey began in 1996 with a high-end gym, but he
soon recognized the need to serve the lower-income population. Inspired by...